Siyu Chen | Pharmacology | Best Researcher Award

Published on by Health Scientists

 Prof. Siyu Chen | Pharmacology | Best Researcher Award

Professor | China Pharmaceutical University | China

Dr. Chen Siyu currently serves as the Deputy Director of the Department of Biochemistry at the School of Life Sciences and Technology, China Pharmaceutical University, where he is also a Professor, Doctoral Supervisor, and Chief Young Scientist of the National Key Research and Development Program. He obtained his academic training in biochemistry and molecular biology, cultivating a strong foundation in metabolic and biochemical sciences. Dr. Chen’s research primarily focuses on Target Discovery and Intervention Strategies for Metabolic Diseases, aiming to elucidate molecular mechanisms and identify novel therapeutic targets for metabolic regulation. He has published extensively as first or corresponding author in leading international journals such as Advanced Science, Nature Communications, and Gut Microbes, with his work widely cited by peers. His innovative research has led to the granting of national patents and multiple ongoing patent applications. Dr. Chen has successfully led major research projects under national and provincial funding programs, including the National Key R&D Program for Young Scientists, the National Natural Science Foundation for Young Scientists, and the Jiangsu Province Excellent Youth Fund. Recognized for his scholarly excellence, he received the Outstanding Doctoral Dissertation Award of Jiangsu Province. In addition to his research, Dr. Chen contributes actively to the academic community as a Young Member of the Metabolism Committee of the Chinese Society of Biochemistry, Director of the Jiangsu Society of Developmental Biology, and Editorial Board Member of Journal of China Pharmaceutical University and Progress in Biochemistry and Biophysics. He also serves as a Guest Editor for Frontiers in Endocrinology and a regular reviewer for leading journals including Journal of Hepatology and ACS Nano. He has 1616 citations from 60 documents with an h-index of 24.

Profiles: Scopus | ORCID

Featured Publications

1. Photosensitive biomimetic nanomedicine-mediated recombination of adipose microenvironments for antiobesity therapy. (2025). Advanced Materials.

2. Wearable photobiomodulation halts thyroid cancer growth by leveraging thyroid photosensitivity. (2025). Bioengineering and Translational Medicine.

3. Blue light-driven cell cycle arrest in thyroid cancer via Retinal-OPN3 complex. (2024). Cell Communication and Signaling.

4. Luteolin detoxifies DEHP and prevents liver injury by degrading Uroc1 protein in mice. (2024). EMBO Molecular Medicine.

5. Rhodiolin inhibits the PI3K/AKT/mTOR signaling pathway via the glycolytic enzyme GPI in human papillary thyroid cancer. (2024). Phytomedicine.

Sina Andalib | Pharmacology | Best Researcher Award

Published on by Health Scientists

Assoc. Prof. Dr. Sina Andalib | Pharmacology | Best Researcher Award

correspond author | Zanjan university of medical sciences | Iran

Dr. Sina Andalib is an Associate Professor at the Department of Pharmacology, Pharmacy Faculty, Zanjan University of Medical Sciences, Iran. He earned his Doctor of Veterinary Medicine (DVM) from Tabriz Azad University in 2005, focusing on anti-inflammatory effects of statins, and completed his PhD at Tabriz University of Medical Sciences in 2013, investigating the cardioprotective effects of Atorvastatin in isoproterenol-induced heart failure in rats. Dr. Andalib’s research spans pharmacology, neurodegenerative diseases, drug delivery systems, and natural product therapeutics, with a particular focus on Alzheimer’s disease, Parkinson’s disease, diabetes, and cancer. He has supervised numerous PhD and PharmD theses exploring innovative nanoparticle-based drug delivery, herbal and synthetic compound interventions, and molecular mechanisms underlying neuroprotection and cardioprotection. His work has been published extensively in high-impact international journals including ACS Chemical Neuroscience, Journal of Pharmaceutical Sciences, International Journal of Pharmaceutics, and European Journal of Pharmacology, covering topics such as nanocomposite hydrogels for wound healing, fullerene-based interventions in Alzheimer’s models, and polypharmacological effects of anticancer compounds. Dr. Andalib has contributed to several internationally collaborative projects, including the development of nanocomposites for neuroprotection and polypharmacological studies of anticancer compounds in organoid models. He has received recognition for his scientific contributions in pharmacology and neurotherapeutics and serves on editorial boards of peer-reviewed journals in pharmacology and drug delivery research. In addition to his research, he holds leadership roles at Zanjan University, including Head of the Department of Pharmacology and Toxicology and Head of the Education Development Office, fostering academic development and innovative research in pharmaceutical sciences. He has 751 citations from 39 documents with an h-index of 15.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Danafar, H., Sharafi, A., Kheiri Manjili, H., & Andalib, S. (2017). Sulforaphane delivery using mPEG–PCL co-polymer nanoparticles to breast cancer cells.

2. Garjani, A., Fathiazad, F., Zakheri, A., Akbari, N. A., Azarmie, Y., Fakhrjoo, A., et al. (2009). The effect of total extract of Securigera securidaca L. seeds on serum lipid profiles, antioxidant status, and vascular function in hypercholesterolemic rats.

3. Barzegar-Jalali, M., Alaei-Beirami, M., Javadzadeh, Y., Mohammadi, G., et al. (2012). Comparison of physicochemical characteristics and drug release of diclofenac sodium–eudragit® RS100 nanoparticles and solid dispersions.

4. Garjani, A., Andalib, S., Biabani, S., Soraya, H., Doustar, Y., & Garjani, A., et al. (2011). Combined atorvastatin and coenzyme Q10 improve the left ventricular function in isoproterenol-induced heart failure in rat.

5. Abedimanesh, N., Asghari, S., Mohammadnejad, K., Daneshvar, Z., et al. (2021). The anti-diabetic effects of betanin in streptozotocin-induced diabetic rats through modulating AMPK/SIRT1/NF-κB signaling pathway.